Literature DB >> 33755090

Azacitidine maintenance after allogeneic hematopoietic cell transplantation for MDS and AML.

Firas El Chaer1, Uma Borate2, Rémy Duléry3, Shernan G Holtan4, Arjun Datt Law5, Lori Muffly6, Samah Nassereddine7, Rory M Shallis8, Kate Stringaris9, Justin Taylor10, Steven M Devine11, Mohamad Mohty3, Christopher S Hourigan9.   

Abstract

Entities:  

Year:  2021        PMID: 33755090      PMCID: PMC7993104          DOI: 10.1182/bloodadvances.2020003839

Source DB:  PubMed          Journal:  Blood Adv        ISSN: 2473-9529


× No keyword cloud information.
  22 in total

1.  Maintenance therapy with low-dose azacitidine after allogeneic hematopoietic stem cell transplantation for recurrent acute myelogenous leukemia or myelodysplastic syndrome: a dose and schedule finding study.

Authors:  Marcos de Lima; Sergio Giralt; Peter F Thall; Leandro de Padua Silva; Roy B Jones; Krishna Komanduri; Thomas M Braun; Hoang Q Nguyen; Richard Champlin; Guillermo Garcia-Manero
Journal:  Cancer       Date:  2010-07-29       Impact factor: 6.860

2.  Measurable residual disease-guided treatment with azacitidine to prevent haematological relapse in patients with myelodysplastic syndrome and acute myeloid leukaemia (RELAZA2): an open-label, multicentre, phase 2 trial.

Authors:  Uwe Platzbecker; Jan Moritz Middeke; Katja Sockel; Regina Herbst; Dominik Wolf; Claudia D Baldus; Uta Oelschlägel; Anke Mütherig; Lars Fransecky; Richard Noppeney; Gesine Bug; Katharina S Götze; Alwin Krämer; Tilmann Bochtler; Matthias Stelljes; Christoph Groth; Antje Schubert; Marika Mende; Friedrich Stölzel; Christine Borkmann; Anne Sophie Kubasch; Malte von Bonin; Hubert Serve; Mathias Hänel; Ulrich Dührsen; Johannes Schetelig; Christoph Röllig; Michael Kramer; Gerhard Ehninger; Martin Bornhäuser; Christian Thiede
Journal:  Lancet Oncol       Date:  2018-11-12       Impact factor: 41.316

3.  A phase 3 randomized study of 5-azacitidine maintenance vs observation after transplant in high-risk AML and MDS patients.

Authors:  Betül Oran; Marcos de Lima; Guillermo Garcia-Manero; Peter F Thall; Ruitao Lin; Uday Popat; Amin M Alousi; Chitra Hosing; Sergio Giralt; Gabriela Rondon; Glenda Woodworth; Richard E Champlin
Journal:  Blood Adv       Date:  2020-11-10

4.  Maintenance azacitidine after myeloablative allogeneic hematopoietic cell transplantation for myeloid malignancies.

Authors:  Kathryn T Maples; Roy T Sabo; John M McCarty; Amir A Toor; Kelly G Hawks
Journal:  Leuk Lymphoma       Date:  2018-04-04

5.  Conditioning regimen intensity and low-dose azacitidine maintenance after allogeneic hematopoietic cell transplantation for acute myeloid leukemia.

Authors:  Naveed Ali; Benjamin Tomlinson; Leland Metheny; Steven C Goldstein; Pingfu Fu; Shufen Cao; Paolo Caimi; Rushang D Patel; Juan Carlos Varela; Luisa Andrade; Jason W Balls; Linda Baer; Megan Smith; Tori Smith; Megan Nelson; Marcos de Lima; Shahram Mori
Journal:  Leuk Lymphoma       Date:  2020-07-10

6.  Shortened-Duration Immunosuppressive Therapy after Nonmyeloablative, Related HLA-Haploidentical or Unrelated Peripheral Blood Grafts and Post-Transplantation Cyclophosphamide.

Authors:  Amy E DeZern; Hany Elmariah; Marianna Zahurak; Gary L Rosner; Douglas E Gladstone; Syed Abbas Ali; Carol Ann Huff; Lode J Swinnen; Phil Imus; Ivan Borrello; Nina D Wagner-Johnston; Richard F Ambinder; Robert A Brodsky; Kenneth Cooke; Leo Luznik; Ephraim J Fuchs; Javier Bolaños-Meade; Richard J Jones
Journal:  Biol Blood Marrow Transplant       Date:  2020-08-18       Impact factor: 5.742

7.  Association of Measurable Residual Disease With Survival Outcomes in Patients With Acute Myeloid Leukemia: A Systematic Review and Meta-analysis.

Authors:  Nicholas J Short; Shouhao Zhou; Chenqi Fu; Donald A Berry; Roland B Walter; Sylvie D Freeman; Christopher S Hourigan; Xuelin Huang; Graciela Nogueras Gonzalez; Hyunsoo Hwang; Xinyue Qi; Hagop Kantarjian; Farhad Ravandi
Journal:  JAMA Oncol       Date:  2020-12-01       Impact factor: 31.777

8.  Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trial.

Authors:  U Platzbecker; M Wermke; J Radke; U Oelschlaegel; F Seltmann; A Kiani; I-M Klut; H Knoth; C Röllig; J Schetelig; B Mohr; X Graehlert; G Ehninger; M Bornhäuser; C Thiede
Journal:  Leukemia       Date:  2011-09-02       Impact factor: 11.528

Review 9.  Minimal residual disease prior to allogeneic hematopoietic cell transplantation in acute myeloid leukemia: a meta-analysis.

Authors:  Sarah A Buckley; Brent L Wood; Megan Othus; Christopher S Hourigan; Celalettin Ustun; Michael A Linden; Todd E DeFor; Michele Malagola; Chloe Anthias; Veronika Valkova; Christopher G Kanakry; Bernd Gruhn; Francesco Buccisano; Beth Devine; Roland B Walter
Journal:  Haematologica       Date:  2017-01-25       Impact factor: 9.941

10.  Impact of Conditioning Intensity of Allogeneic Transplantation for Acute Myeloid Leukemia With Genomic Evidence of Residual Disease.

Authors:  Christopher S Hourigan; Laura W Dillon; Gege Gui; Brent R Logan; Mingwei Fei; Jack Ghannam; Yuesheng Li; Abel Licon; Edwin P Alyea; Asad Bashey; H Joachim Deeg; Steven M Devine; Hugo F Fernandez; Sergio Giralt; Mehdi Hamadani; Alan Howard; Richard T Maziarz; David L Porter; Bart L Scott; Erica D Warlick; Marcelo C Pasquini; Mitchell E Horwitz
Journal:  J Clin Oncol       Date:  2019-12-20       Impact factor: 44.544

View more
  3 in total

1.  Hypomethylating Agents and FLT3 Inhibitors As Maintenance Treatment for Acute Myeloid Leukemia and Myelodysplastic Syndrome After Allogeneic Hematopoietic Stem Cell Transplantation-A Systematic Review and Meta-Analysis.

Authors:  Jan Philipp Bewersdorf; Cecily Allen; Abu-Sayeef Mirza; Alyssa A Grimshaw; Smith Giri; Nikolai A Podoltsev; Lohith Gowda; Christina Cho; Martin S Tallman; Amer M Zeidan; Maximilian Stahl
Journal:  Transplant Cell Ther       Date:  2021-09-20

Review 2.  Prevention and Treatment of Acute Myeloid Leukemia Relapse after Hematopoietic Stem Cell Transplantation: The State of the Art and Future Perspectives.

Authors:  Salvatore Leotta; Annalisa Condorelli; Roberta Sciortino; Giulio Antonio Milone; Claudia Bellofiore; Bruno Garibaldi; Giovanni Schininà; Andrea Spadaro; Alessandra Cupri; Giuseppe Milone
Journal:  J Clin Med       Date:  2022-01-04       Impact factor: 4.241

Review 3.  Current Status and Perspectives of Allogeneic Hematopoietic Stem Cell Transplantation in Elderly Patients with Acute Myeloid Leukemia.

Authors:  Servais Sophie; Beguin Yves; Baron Frédéric
Journal:  Stem Cells Transl Med       Date:  2022-05-27       Impact factor: 7.655

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.